Stabilization of intracellular trafficking and metabolism of amyloid β-protein precursor and Alcadein β by apolipoprotein E  by Kimura, Ayano et al.
FEBS Letters 589 (2015) 2394–2400journal homepage: www.FEBSLetters .orgStabilization of intracellular trafﬁcking and metabolism of amyloid
b-protein precursor and Alcadein b by apolipoprotein Ehttp://dx.doi.org/10.1016/j.febslet.2015.07.017
0014-5793/ 2015 Federation of European Biochemical Societies. Published by Elsevier B.V. All rights reserved.
Abbreviations: AD, Alzheimer’s disease; Alcs, Alcadein family proteins; Alca,
Alcadein a; Alcb, Alcadein b; Alcc, Alcadein c; APP, amyloid b-protein precursor; Ab,
b-amyloid; p3-Alc, small peptide generated by a-and c-site cleavages of Alc; sAlc,
amino-terminal extracellular domain fragments of Alc secreted by a cleavage of Alc
by primary secretase; sAPP, amino-terminal extracellular domain fragments of APP
secreted by cleavage of APP by primary secretases
Author contributions: AK carried out all the experiments. SH and TS participated in
the design of the study and the writing of the manuscript. TS conceived the study
and was the primary author of the manuscript. All authors read and approved the
ﬁnal manuscript.
⇑ Corresponding author at: Laboratory of Neuroscience, Graduate School of
Pharmaceutical Sciences, Hokkaido University, Kita12-Nishi6, Kita-ku, Sapporo
060-0812, Japan. Fax: +81 11 706 4991.
E-mail address: tsuzuki@pharm.hokudai.ac.jp (T. Suzuki).Ayano Kimura, Saori Hata, Toshiharu Suzuki ⇑
Laboratory of Neuroscience, Graduate School of Pharmaceutical Sciences, Hokkaido University, Sapporo 060-0812, Japan
a r t i c l e i n f oArticle history:
Received 18 May 2015
Revised 8 July 2015
Accepted 14 July 2015
Available online 23 July 2015
Edited by Jesus Avila
Keywords:
Amyloid b-protein precursor
Alcadein
Apolipoprotein E
Alzheimer’s diseasea b s t r a c t
Intracellular metabolism of amyloid b-protein precursor (APP) is important for the pathogenesis of
Alzheimer’s disease (AD). Alcadeins (Alca, Alcb, and Alcc) are neural membrane proteins similar to
APP in their localization, metabolism, and cellular function. Isoform e4 of apolipoprotein E (ApoE) is
a major risk factor for AD. We found that ApoE expression attenuated intracellular trafﬁcking of APP
and Alcb, resulting in metabolic stabilization of both proteins. By contrast, Alca intracellular prote-
olysis was facilitated by ApoE expression, which was not due to an increase in the primary cleavage
of Alca. This difference may result from binding of ApoE to membrane proteins.
 2015 Federation of European Biochemical Societies. Published by Elsevier B.V. All rights reserved.1. Introduction
Alzheimer’s amyloid b-protein precursor (APP) is a type I mem-
brane protein from which amyloid-b protein (Ab) is generated by
serial proteolytic cleavages [1,2]. The Alcadeins (Alcs) are a family
of evolutionarily conserved neural type I membrane proteins, Alca,
Alcb, and Alcc, being Alca and Alcb highly expressed in adult neu-
rons. Alca was isolated as a binding partner of neural adaptor pro-
tein X11-like (X11L), and is therefore also called XB31
(X11L-binding protein clone number 31); they were also character-
ized as postsynaptic calcium-binding proteins, calsyntenins [3,4].
Because X11L itself was identiﬁed as an APP binding partner, Alc
and APP are prone to form a tripartite complex mediated bycytoplasmic X11L [3,5,6]. Therefore, Alc colocalizes extensively
with APP in healthy neurons and also in dystrophic neurites in
senile plaques of Alzheimer’s disease (AD) patients [3].
Both APP and Alcs are cleaved primarily at the juxtamembrane
region by APP a-secretase (ADAM 10 and ADAM 17). These cleav-
ages result in secretion of large N-terminal fragments, sAPPa and
sAlcs, into the extracellular milieu, along with generation of the
membrane-associated C-terminal fragments APP CTFa and Alc
CTF [6,7]. APP, but not Alc, is also subject to an alternative primary
cleavage by b-secretase (BACE1) in endosomes to generate amy-
loidogenic APP CTFb [8]. The APP CTFs and Alc CTF are further
cleaved by c-secretase, which generates p3 peptide from APP
CTFa, Ab from APP CTFb, and p3-Alc peptide from Alc CTF [1,7,9].
Thus, it is conceivable that APP and Alcs are subjected to similar
metabolic regulation in neurons [1,10]. Furthermore, Alc is subject
to intracellular transport by kinesin-1 in neurons, as is APP, indi-
cating that both Alc and APP may share similar metabolic fates
during intracellular transport [11–16].
While the role of APP is clear in AD [1,2,8], the contribution of
Alc and its metabolic fragments in AD pathogenesis has not been
fully analyzed. Because both APP and Alca/calsyntenin-1 function
as major anterograde vesicular cargos of kinesin-1,
well-organized performance of both cargo-receptor proteins may
be important for a persistence of neuronal functions, and the inap-
propriate interactions of Alca- and APP-containing vesicles with
kinesin-1 are thought to promote aberrant APP metabolism includ-
ing the increased generation of Ab [12,17,18]. Furthermore,
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and/or function [19,20], suggesting that Alcb may involve in
Ab-induced neurotoxicity.
For sporadic AD, which is not associated with pathogenic muta-
tions in any of three major causative genes, APP, presenilinl (PS1), or
presenilin2 (PS2), the predominant risk factor is apolipoprotein E
isoform e4 (ApoE4), a protein that may be involved in Ab clearance
[21,22]. However, it remains unknown whether ApoE participates
in the intracellular metabolism of APP and Alcs. In this study, we
examined the effect of ApoE expression on intracellular trafﬁcking
and metabolism of APP and Alcs.
2. Materials and methods
2.1. Plasmid construction
The human Alcadein cDNAs, pcDNA3.1-Alca and
pcDNA3.1-Alcb, and FLAG-tagged pcDNA3.1-FLAG-Alca and
pcDNA3.1-FLAG-Alcb, were described previously [7]. Human
APP695 cDNAs, pcDNA3.1-APP, and pcDNA3.1-FLAG-APP were
described previously [23,24]. Human ApoE4 cDNA was prepared
from brain of the human ApoE4 knock-in mouse [25], and human
ApoE2 and ApoE3 cDNAs were prepared from ApoE4 cDNA with
megaprimers and Ex Taq polymerase (Takara Bio). These ApoE
cDNAs were inserted into the pcDNA3.1 vector at EcoRI/XhoI sites
to generate pcDNA3.1-ApoE4, pcDNA3.1-ApoE3 and
pcDNA3.1-ApoE2. The same cDNAs were also inserted into
pcDNA3.1-C-FLAG and pcDNA3.1-C-HA vectors to generate
pcDNA3.1-ApoE-FLAG and pcDNA3.1-ApoE-HA, which express
C-terminal tagged ApoE proteins in cell. The FLAG-tagged human
Alca HA mutant cDNA was prepared by PCR; speciﬁcally, the DNA
sequence encoding nine amino acids, A-N-H-M-A-A-Q-P-Q, around
the a-secretase cleavage sites was replaced with a DNA sequence
encoding the HA-tag to yield pcDNA3.1-FLAG-Alca HAmut.
2.2. Transfection of cells, Western blot analysis, and co-
immunoprecipitation assay
Neuro-2a (N2a) mouse neuroblastoma cells (0.3–1.0  106)
were transiently transfected with the indicated amounts of plas-
mid using Lipofectamine 2000 (Invitrogen/Life Technologies).
After transfection for 24–30 h, the medium was changed for fur-
ther culture. To analyze cellular proteins, cells were harvested
and lysed in a radioimmunoprecipitation assay (RIPA) buffer con-
taining protease inhibitor cocktail. In order to analyze secreted
proteins, FLAG-tagged sAlca, sAlcb, and sAPP were recovered from
conditioned medium by immunoprecipitation with an anti-FLAG
antibody and Protein G-Sepharose. Cell lysates and the immuno-
precipitates were analyzed by Western blotting with the indicated
antibodies, detected by ECL (GE Healthcare), and quantitated using
VersaDoc Model 3000 (Bio-Rad Laboratries).
In co-immunoprecipitation assays, cells were lysed with CHAPS
lysis buffer (10 mM CHAPS in PBS including a protease inhibitor
cocktail). After centrifugation (15,000g for 10 min), the indicated
antibodies and Protein G-Sepharose beads were added to the lysate
supernatant and incubated for 8–12 h with agitation. The beads
were recovered by centrifugation and washed with CHAPS lysis
buffer, and the immunoprecipitates were analyzed by Western
blotting using the indicated primary antibodies along with horse-
radish peroxidase (HRP)-linked anti-rabbit or anti-mouse IgG sec-
ondary antibody.
2.3. Cell-surface biotinylation
Cells were washed with ice-cold PBS and incubated with
0.5 mg/mL of NHS-LC-Biotin (Thermo Fisher Scientiﬁc) in PBS for30 min at 4 C. The cells were further incubated with ice-cold
50 mM glycine in PBS for 5 min and washed with ice-cold PBS,
and then subjected to lysis in RIPA buffer containing protease inhi-
bitor cocktail. After centrifugation (15,000g for 10 min),
NeutrAvidin agarose beads (Thermo Fisher Scientiﬁc) were added
to the supernatant of the lysate and incubated for 2 h under rota-
tion. The beads were recovered by centrifugation and washed with
RIPA buffer, and the bound proteins were analyzed by Western
blotting.
2.4. Antibodies
Monoclonal mouse anti-FLAG (M2, Sigma–Aldrich), anti-HA
(12CA5, BD Biosciences) and anti-a-tubulin (DM1A, Santa Cruz
Biotechnology) antibodies, and polyclonal rabbit anti-human
ApoE (#18171, IBL), anti-APP C-terminal (#8717, Sigma–Aldrich)
antibodies were purchased from the indicated suppliers.
Polyclonal sheep anti-mouse IgG HRP-linked species-speciﬁc
whole antibody (NA931) and donkey anti-rabbit IgG HRP-linked
species-speciﬁc whole antibody (NA934) were purchased from
GE Healthcare. Polyclonal rabbit anti-Alcadein a (#83) and
anti-Alcadein b (#99) antibodies were described previously [6].
3. Results
3.1. Stabilization of intracellular metabolism of APP and Alcb, but not
Alca
To investigate the basic intracellular metabolism of APP and
major Alc species, Alca and Alcb, under the expression of ApoE,
we performed a pulse-chase study in the presence or absence of
ApoE4 expression (Fig. 1). N2a cells expressing APP, Alca, and
Alcbwith or without ApoE4 were cultured in the presence of cyclo-
heximide, and cells were harvested at the indicated times for anal-
ysis of intracellular protein metabolism by Western blotting.
Consistent with a previous report [26], immature APP (imAPP)
with N-glycosylation was subject to O-glycosylation during matu-
ration in the late Golgi, and mature APP (mAPP) gradually disap-
peared as a result of cleavage by APP a- and/or b-secretases
(Fig. 1A). The half-life of total APP (mAPP plus imAPP) metabolism
was 42.7 ± 3.8 min. In the presence of ApoE4, mAPP metabolism
was not changed (i.e., the half-lives of mAPP in the presence or
absence of ApoE4 were almost identical), whereas the imAPP level
was not reduced. The observation indicates that ApoE4 expression
suppressed APP maturation, which means that ApoE4 may attenu-
ate the intracellular transport of APP into the late secretory path-
way; consequently, the intracellular level of imAPP did not
decrease. Therefore, the half-life of total APP metabolism was sig-
niﬁcantly stabilized (to 75.0 ± 9.6 min) in the presence of ApoE4,
regardless of the invariant rates of mAPP metabolism.
This tendency was also observed for Alcb (Fig. 1C). The half-life
of total Alcb (both Alcb with either complex or high-mannose
N-glycans) was slightly extended (to 197.8 ± 37.3 min in the pres-
ence of ApoE4 from 136.4 ± 13.6 min in the absence of ApoE4,
although this difference was not statistically signiﬁcant at the time
points studied. However, Alcb with high-mannose N-glycan
(hAlcb) tended to exhibit a longer half-life and was statistically sig-
niﬁcant at 240 min in the presence of ApoE4, suggesting again that
ApoE4 attenuates Alcb intracellular transport by retaining hAlcb
for a longer time in the early secretory pathway, as in the case of
imAPP. As for mAPP, the metabolism of Alcb with complex
N-glycan (cAlcb) in the presence of ApoE was almost the same in
the absence of ApoE.
In contrast to APP and Alcb, the half-life of total Alca was short-
ened to 44.3 ± 7.3 min in the presence of ApoE4 from 73.1 ± 14.0 in
the absence of ApoE4 (Fig. 1B). This change in the total amount of
Fig. 1. Pulse-chase analysis of Alca, Alcb, and APP: Effect of ApoE expression N2a cells were transiently transfected with APP (A), Alca (B), or Alcb (C) plasmid (0.3 lg) with or
without ApoE4 plasmid (0.1 lg), and then cultured for 26 h. Cells were further cultured in a medium containing cycloheximide (0.1 mg/mL) for the indicated chase time (min)
and harvested. Cell lysates were analyzed by Western blotting with anti-Alca, anti-Alcb, anti-APP, anti-ApoE, and anti-a-tubulin antibodies. APP (A) with N-glycan alone
(imAPP) or both N- and O-glycans (mAPP) was quantitated along with the total amount of APP (mAPP plus imAPP). Alca (B) and Alcb (C) with complex N-glycan (cAlc) or high-
mannose N-glycan (hAlc) was quantitated along with the total amount of Alc (cAlc plus hAlc). Closed squares indicate metabolism of APP and Alc in cells without co-
expression of ApoE4, and open squares indicate metabolism of APP and Alc in cells co-expressing ApoE4. The value at 0 min was deﬁned as 1.0; values shown represent
means ± S.E. Asterisks indicate statistical signiﬁcance as determined by Student’s t-test (n = 3 in panel A and n = 4 in panels B and C; *P < 0.05; **P < 0.01).
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was statistically signiﬁcant at 30 and 60 min, indicating that meta-
bolism of Alca was facilitated in the presence of ApoE4. cAlca and
hAlca also showed a shorter half-life, signiﬁcantly at 30 and/or
60 min. Overall, intracellular metabolism Alca, in contrast to that
of Alcb and APP, was facilitated or at least not delayed by
co-expression of ApoE4. ApoE4 levels also decreased gradually
along with chase time because cellular ApoE was secreted.
ApoE4 is the isoform associated with the greatest risk of AD
onset, and it differs from ApoE2 and ApoE3 in various functions
including AP metabolism [27,28]. To reveal the effect of ApoE iso-
forms on the intracellular behavior of APP and Alc, we examined
ApoE isoform-speciﬁc effects. In these experiments, APP or Alc
was expressed in N2a cells with ApoE e2, e3, or e4 isoforms, and
changes of intracellular Alc and APP levels were examined by
Western blotting (Fig. 2). All ApoE isoforms decreased the intracel-
lular Alca level to the same extent statistically signiﬁcantly, but
had no effect on Alcb and APP levels, indicating that the effect of
ApoE on intracellular APP and Alc metabolism is
isoform-independent. ApoE4 and ApoE3 protein expression levels
were slightly lower than that of ApoE2, regardless of the almost
equal levels of mRNA (Fig. 2B and C), possibly reﬂecting a differ-
ence in stability among ApoE isoforms in the cell. Hereafter, we
used ApoE4 for further analysis.
3.2. Primary cleavage of APP and Alc is not altered by co-expression of
ApoE
The results of the pulse-chase study suggested that ApoE
expression does not alter the primary cleavages of APP and Alcs:
the reductions in the levels of mAPP and cAlcs, which predomi-
nantly appear on the cell surface, were not remarkable in the pres-
ence of ApoE. However, in contrast to imAPP, which stays in the ERand early Golgi, hAlcs appeared at some level on the cell surface,
where they were cleaved by a-secretase. Therefore, a reduction
in intracellular Alca level may be caused by elevated primary
cleavage of Alca, but not APP or Alcb. We investigated whether
ApoE co-expression promoted the primary cleavage of APP and/or
Alcs. Following primary cleavage, the amino-terminal regions of
APP and Alcs are secreted as sAPP, sAlca, and sAlcb respectively,
[7]. We investigated changes in primary cleavage in cells express-
ing APP, Alca, or Alcb, with or without co-expression of ApoE4
(Fig. 3). Medium of N2a cells expressing FLAG-tagged APP, Alca,
or Alcb, together with or without ApoE4-HA, were subjected to
immunoprecipitation with FLAG antibody and the immunoprecip-
itates were examined by Western blotting with the same antibody.
Notably, production of all three amino-terminal regions (sAPP,
sAlca, and sAlcb) was decreased when ApoE4 was co-expressed
(Fig. 3A): generation of sAPP and sAlcb decreased by 80%,
whereas sAlca secretion decreased by 50%. The reductions in
APP and Alcb cleavage may be due to the slight decrease in
cell-surface APP and Alcb (Fig. 3B), which resulted in metabolic sta-
bilization by ApoE expression (Fig. 1).
In contrast to APP and Alcb, the cleavage of Alca signiﬁcantly
decreased (Fig. 3A), and the cell-surface level of Alca clearly
increased (Fig. 3B). This observation indicates that cell-surface
cleavage of Alca by a-secretase does not contribute to the reduced
level of intracellular Alca in cells expressing ApoE4.
To conﬁrm this ﬁnding, we introduced amino-acid substitu-
tions around the primary cleavage site (Fig. 4A). When the result-
ing mutant, Alca (HAmut), containing the HA-tag sequence
instead of the a-cleavage sequence, was expressed in N2a cells,
Alca HAmut was remarkably stable with respect to primary
cleavage. Large amounts of Alca HAmut, especially cAlca, were
detected relative to Alca in wild-type (WT) in cells without
ApoE4 expression (Fig. 4B, ). By contrast, the intracellular levels
Fig. 2. Effect of ApoE on the metabolism of APP and Alcs is isoform-independent. (A) N2a cells were transiently transfected with APP, Alca, or Alcb plasmid (0.3 lg) along with
ApoE2, ApoE3, or ApoE4 plasmid (0.1 lg), and then cultured for 24 h. Minus () indicates empty vector alone. APP, Alca, and Alcbwere detected byWestern blotting and their
expression levels were quantitated (n = 5). The value in the absence () of ApoE expression was deﬁned as 1.0; values shown represent means ± S.E. The asterisks indicate
statistical signiﬁcance as determined by Tukey’s multiple comparison test (*P < 0.05; **P < 0.01). n.s, not signiﬁcant. (B) Protein expression levels of ApoE isoforms in panel A
were quantitated. The value in the presence of ApoE2 expression was deﬁned as 1.0; values shown represent means ± S.E. The asterisks indicate statistical signiﬁcance as
determined by Dunnett’s multiple comparison test (n = 5; **P < 0.01; ***P < 0.001). (C) mRNA expression levels of ApoE isoforms were conﬁrmed by RT-PCR, and the ampliﬁed
products were quantitated alongwith the level of b-actinmRNA. The value in the presence of ApoE2 expressionwas deﬁned as 1.0; values shown representmeans ± S.E. (n = 5).
Fig. 3. Primary cleavage and cell-surface levels of APP and Alcs in cells expressing ApoE. (A) Effect of ApoE4 on primary cleavage of APP, Alca, and Alcb. N2a cells were
transiently transfected with FLAG-tagged APP, Alca, or Alcb plasmids (0.3 lg) in the presence (+) or absence () of ApoE4-HA plasmid (0.1 lg). (upper panel) FLAG-sAPP,
FLAG-sAlca, and FLAG-sAlcb secreted into the mediumwere recovered by immunoprecipitation with FLAG antibody, detected byWestern blotting with the same antibody, or
quantitated. (lower panel) The value in the absence () of ApoE4 expression was deﬁned as 1.0; values shown represent means ± S.E. The asterisks indicate statistical
signiﬁcance as determined by Student’s t-test (n = 3; *P < 0.05; **P < 0.01). (B) Effect of ApoE4 on cell-surface localization of APP, Alca, and Alcb. N2a cells were transiently
transfected with FLAG-tagged APP, Alca, and Alcb plasmids (0.3 lg) in the presence (+) or absence () of ApoE4-HA plasmid (0.1 lg). The cell-surface biotinylated proteins
were recovered from cell lysates with NeutrAvidin beads. (Upper panel) Lysates (total) and biotinylated proteins (cell-surface) were analyzed by Western blotting with FLAG,
ApoE, and a-tubulin antibodies. (Lower panel) Cell-surface levels of APP, Alca, and Alcb in the presence (+) or absence () of ApoE4 expression. Values in the absence of ApoE4
were deﬁned as 1.0; values shown represent means ± S.E. The asterisks indicate statistical signiﬁcance as determined by Student’s t-test (n = 4; *P < 0.051).
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Fig. 4. Intracellular metabolism of primary cleavage-resistant Alca mutant in cells with or without expression of ApoE4 (A) Schematic structure of Alca and amino-acid
sequence around a cleavage site of a-secretase. In the HA mutant (HAmut), the amino-acid sequence of Alca wild-type (WT) was replaced with the HA-tag sequence, which
prevents Alca from undergoing primary cleavage. (B) Effect of HA mutation on cellular metabolism of Alca upon co-expression of ApoE4. N2a cells were transiently
transfected with FLAG-tagged wild-type (WT) or HA-mutated (HAmut) Alca plasmid (0.3 lg) in the presence (+) or absence () of ApoE4 plasmid (0.1 lg). (Left panel) Cell
lysates were analyzed by Western blotting with FLAG and ApoE antibodies, and Alca with complex N-glycan (cAlca) and high-mannose N-glycan (hAlca) were detected.
(Right panel) Total amount of Alca (cAlca plus hAlca) was quantitated. The values in the absence () of ApoE4 expression were deﬁned as 1.0; values shown represent
means ± S.E. The asterisks indicate statistical signiﬁcance as determined by Student’s t-test (n = 3; ***P < 0.001).
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co-expression of ApoE4. These data strongly indicate that the
reduction in the level of Alca in cells expressing ApoE is not
due to an increase in primary cleavage. Furthermore, except for
the primary cleavage, Alca was subject to more intracellular
degradation in the presence of ApoE.
3.3. Interactions of ApoE4 with APP and Alc
ApoE and the extracellular/luminal region of APP and Alcs may
face the lumen of organelles and transport vesicles in the secretoryFig. 5. Binding of ApoE to APP and Alcs. N2a cells were transiently transfected with (A) AP
(0.3 lg). Cell lysates were subject to co-immunoprecipitation with FLAG antibody, and i
and Alcb antibodies along with FLAG and a-tubulin antibodies. mAPP, APP with N- and O-
with high-mannose N-glycan.pathway. Hence, we asked whether intracellular ApoE can bind Alc
or APP.
N2a cells expressing APP, Alca, or Alcb with ApoE4-FLAG were
lysed, and co-immunoprecipitation assay was performed using
the FLAG antibody (Fig. 5). The antibody co-immunoprecipitated
Alcb with high-mannose N-glycan along with FLAG-ApoE4
(Fig. 5C), whereas FLAG-ApoE4 did not co-precipitate Alca
(Fig. 5B). The data show that ApoE4 associates with Alcb in the
ER or early Golgi, but not in the late secretory pathway. ApoE4
bound neither hAlca nor cAlca, indicating that Alca and ApoE do
not engage in intracellular interaction.P, (B) Alca, or (C) Alcb plasmid (0.6 lg) with (+) or without () ApoE4-FLAG plasmid
mmunoprecipitates and lysates were detected by Western blotting with APP, Alca,
glycans; imAPP, APP with N-glycan alone; cAlc, Alc with complex N-glycan; hAlc, Alc
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the presence or absence of ApoE4. N2a cells were transiently
expressed with FLAG-tagged APP, Alca and Alcb in the presence
or absence of ApoE4-EGFP expression, and subjected to immunos-
taing analysis with anti-FLAG and anti-EGFP antibodies. APP and
Alcb were strongly collocalized with ApoE4 in perinuclear
Golgi-like structure (white color in merged panels), and the signals
of APP and Alcb in cytoplasmic region decreased when compared
to these in cells without ApoE4 expression (magenta color in
merge panels), while the localization of Alcawere largely indepen-
dent of ApoE4 staining in Golgi and detectable in the cytoplasmic
region even in the presence of ApoE4 (Supplementary ﬁgure).
These observations support that ApoE4 associates to APP and
Alcb, but not to Alca, to untransport APP and Alcb in perinuclear
early secretory compartment.
The interaction of hAlcb with ApoE is consistent with the
stabilized intracellular metabolism of hAlcb, in contrast to that
of cAlcb (Fig. 1). Alcb may include the ApoE-binding domain, and
the complex N-glycan of Alcb may inhibit ApoE binding. ApoE4
weakly bound both mature and immature APP (Fig. 5A), consistent
with reports that the Ab sequence and amino-terminal
ecto-domain of APP bind to ApoE [29,30]. Thus, it is conceivable
that among APP, Alca, and Alcb, only Alca cannot bind ApoE
intracellularly, and that proteolysis of Alca is facilitated en route
to the cell surface [31].
4. Discussion
In this study, we investigated the effect of ApoE expression on
the intracellular metabolism of APP and Alcs. We made several
key observations: (i) APP metabolism was slowed down in the
presence of ApoE by attenuation of the intracellular trafﬁcking of
APP, resulting in slower maturation of APP in the late secretory
pathway; Alcb also exhibited a similar tendency. However, Alca
exhibited different intracellular metabolism when ApoE was
co-expressed. ApoE did not metabolically stabilize Alca via attenu-
ation of Alca intracellular trafﬁcking, and the intracellular level of
Alca was reduced in the presence of ApoE. (ii) The effect of ApoE is
not isoform-speciﬁc, and may depend on the binding between type
I membrane protein and ApoE. (iii) ApoE did not inﬂuence the pri-
mary cleavage of APP and Alcs, although the attenuated intracellu-
lar trafﬁcking of APP and Alcb decreased the secretion of the
primary cleavage products. (iv) The intracellular level of Alca
decreased regardless of primary cleavage of Alca, suggesting that
intracellular proteolysis of Alca was facilitated by co-expression
of ApoE.
Although the results summarized above are not sufﬁcient to
understand the molecular mechanism underlying the effect of
ApoE co-expression on the intracellular behavior of APP and Alcs,
these results suggest that ApoE stabilizes the metabolism and
intracellular trafﬁcking of APP and Alcb, probably by luminal bind-
ing of ApoE to APP and Alcb. Furthermore, ApoE expression may
facilitate Alca intracellular metabolism. Notably, Alca tends to be
subject to constitutive proteolysis prior to cell-surface exposure
[31]. In fact, the cell-surface level of Alca is lower than those of
APP and Alcb, regardless of ApoE expression (Fig. 3B). ApoE expres-
sion might facilitate this constitutive proteolysis of Alca via an
unidentiﬁed regulatory mechanism.
ApoE is usually synthesized in glial cells, whereas the ApoE
receptor is expressed in neurons [27,32]. However, several studies
have demonstrated neural expression of ApoE [33,34] and the par-
ticular functions of neural ApoE in the neurodegenerative state
have been reported [35–37]. Moreover, the differences in the intra-
cellular metabolism of Alca relative to that of APP and Alcb in
response to ApoE co-expression suggests a possible role for ApoE
in an intracellular trafﬁcking of membrane proteins. APP and Alcsare cargo receptors that associate with the kinesin-1 motor [12–
14,16,17] and recruit various proteins into cargo vesicles. The
interaction of ApoE with the luminal/extracellular domain of
cargo-receptor may inﬂuence the cytoplasmic structure of cargo
receptors to regulate intracellular trafﬁcking of cargo vesicles.
Although analysis of this mechanism will require investigation,
the present ﬁndings regarding the metabolic stabilization of APP
by ApoE provides an insight into the pathobiology of AD, including
the regulation of Ab generation.
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